Sugi Predict

Sugi Predict / Compounds / SCHEMBL17396753

SCHEMBL17396753

SCHEMBL17396753

CCOC(=O)Cc1cc(C(F)(F)F)ccn1.[LiH]

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ GAA P10253 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ POLB P06746 4/20 0.45
▸ SYK P43405 3/20 0.43
▸ MBOAT4 Q96T53 1/20 0.42
▸ GRIN1 Q05586 2/20 0.42
▸ GRIN2B Q13224 2/20 0.42
▸ MAPT P10636 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ CCNE1 P24864 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ CYP1A2 P05177 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427075 0.99 L3MBTL1 (0.55) L3MBTL1GAAALDH1A1POLBSYK
SCHEMBL2771208 0.85 L3MBTL1 (0.53) L3MBTL1GAAALDH1A1POLBSYK
SCHEMBL15505079 0.84 ALDH1A1 (0.48) L3MBTL1GAAALDH1A1SYKMAPT
SCHEMBL17665726 0.82 ALDH1A1 (0.43) L3MBTL1GAAALDH1A1MBOAT4CCNE1
SCHEMBL17396651 0.81 NPC1 (0.50) L3MBTL1GAAALDH1A1POLBSYK
SCHEMBL3548646 0.79 TDP1 (0.44) ALDH1A1POLBMAPTMEN1KMT2A
SCHEMBL17396700 0.79 AGBL2 (0.46) L3MBTL1GAAALDH1A1MBOAT4
SCHEMBL15464519 0.78 GAA (0.54) L3MBTL1GAAALDH1A1MAPT
SCHEMBL29755981 0.77 AGBL2 (0.47) L3MBTL1GAAALDH1A1MBOAT4
SCHEMBL17396703 0.77 AGBL2 (0.47) L3MBTL1GAAALDH1A1MBOAT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-10-31 — — US disclosed
US-11958849-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2024-04-16 — — US disclosed
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2023-04-20 — — US disclosed
US-11370786-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-06-28 — — US disclosed
CN-107074805-B GLS1 inhibitors for the treatment of disease 德州大学系统董事会 2021-02-26 — — CN disclosed
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2020-12-31 — — US disclosed
US-10766892-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-09-08 — — US disclosed
EP-3677579-A1 HETEROCYCLIC GLS1 INHIBITORS Board of Regents, The University of Texas System (US) 2020-07-08 — — EP disclosed
EP-3164394-B1 GLS1 INHIBITORS FOR TREATING DISEASES UNIV TEXAS (US) 2020-04-01 — — EP disclosed
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2019-09-05 — — US disclosed
US-10344025-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2019-07-09 — — US disclosed
US-9809588-B2 GLS1 inhibitors for treating disease BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2017-11-07 — — US disclosed
US-20170291895-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2017-10-12 — — US disclosed
EP-3164394-A2 GLS1 INHIBITORS FOR TREATING DISEASE Board of Regents, The University of Texas System (US) 2017-05-10 — — EP disclosed
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-14 — — US disclosed
WO-2016004404-A2 GLS1 INHIBITORS FOR TREATING DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2016-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344025-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20240360121-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20230124815-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20160009704-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-10766892-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-11370786-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLB1 L3MBTL1 1989/4885GAA 139/4885ALDH1A1 766/4885
US-11958849-B2 GLS1 inhibitors for treating disease GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20200407353-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20170291895-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885
US-20190270736-A1 GLS1 INHIBITORS FOR TREATING DISEASE GLS2, GLS, GLG1 L3MBTL1 1762/4885GAA 89/4885ALDH1A1 882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.